Terumo India Introduces Innovative Solutions for Liver Cancer

Terumo India, the Indian subsidiary of the global medical technology leader Terumo Corporation, has announced the release of Occlusafe and LifePearl for the treatment of liver cancer.Hepatocellular carcinoma (HCC) is the prevalent form of primary liver cancer, with over 20,000 new cases diagnosed annually in India. There are various management approaches to treat HCC, including surgical resection and minimally invasive options.Embolization is a minimally invasive treatment option that can be considered. Here, the tumor's blood supply is cut off. By depriving the tumor of nutrients and oxygen, it leads to the death of the tumor cells. Transcatheter Arterial Chemo-Embolization (TACE) is the most frequently used type of Embolization. It is a minimally invasive option for treating intermediate stage liver cancer, recommended by clinical guidelines.Terumo, a Japan-based company, has introduced an advanced therapy known as Balloon-TACE (B-TACE) for the treatment of liver cancer in India for the first time. Occlusafe, Terumo’s B-TACE device, provides patients with a more precise and targeted method of delivering chemotherapy drugs to the tumor, resulting in significant benefits. Furthermore, the impact on nearby healthy tissues is kept to a minimum. This is linked to better response rates, with a much lower need for repeated treatments compared to TACE alone. This has the potential to protect liver function.Dr. Shishir Agarwal from Terumo India emphasized that the therapy is aimed at contributing to society through healthcare, as part of the company's mission. Our goal is to introduce the most up-todate Japanese medical technologies in India in order to elevate the standard of care for patients and healthcare providers. In India, Occlusafe and Lifepearl will provide additional treatment options for liver cancer care.